Discovering and connecting data to build new algorithms, AI and machine learning approaches

Leveraging the UK’s renowned leadership in drug discovery – a modern approach to R&D

Virtual R&D is the delivery of medicines R&D using multiple best-in-class partners, ensuring the critical value-based experiments are done by the right people, data is captured, and IP-estate is secured.

Brokering easier access to consented patient data and samples

The UK has millions of samples and billions of data points collected from UK patients who have agreed that their samples and data can be used for research. But small UK medical research companies struggle to access them.

Blog

The role of kinases in human disease is well known in the drug discovery world, making them significant therapeutic intervention points. There are over 500 known kinases in the human kinome and over 150 are mutated or misregulated in various disease states. However, developing a selective kinase inhibitor can be both challenging and time consuming. […]

At Medicines Discovery Catapult we like to collaborate and help young data scientists get into pharma. “The best minds of my generation are thinking about how to make people click ads. That sucks.” – Jeff Hammerbacher That’s why we have partnered with University of Sheffield Data Analytics MSc. Providing a project and dataset that will […]

One of our collaborators, Intellegens, recently published a great paper in JCIM – Imputation of Assay Bioactivity Data Using Data Learning – focusing on applying Deep Learning approaches to tackle the problem of sparse data, a recurring issue in drug discovery. Sparse data typically arise when compounds are being assayed against multiple biological targets, but […]

Medicines Discovery Catapult and the BioIndustry Association stated in their 2018 State of the Discovery Nation Report, that: “… over 80% of SMEs surveyed agreed that access to biosamples is hugely important for commercial development” and “… as many as 80% found accessing UK samples unexpectedly difficult…” A major recommendation of this report was that […]

In recent years, machine learning and Artificial Intelligence (AI) have become widely popularised in all areas of modern life, and drug discovery is no exception. Why AI? The benefit of AI for detecting novel drug-target interactions, or even in silico design of novel drug-like compounds, is clear. The possible chemical search space of potentially synthesizable […]

Among the wealth and diversity of stakeholders that bring science out of the laboratories and closer to patients, charities are usually regarded as the hands-off funders of research. However, an increasing number of biomedical research charities have been taking a more proactive and involved role in boosting innovation in the therapeutic areas they support. Action […]

1. What challenges have you faced, as a woman, entering this industry? The biggest by far is Imposter Syndrome, I think most people will suffer from this at some point in their lives (and I don’t just mean women!). It’s not an easy one to overcome either – and the only advice I can offer […]

It is now over ten years since John Ioannidis published his essay on ‘Why most published findings are false’. This paper presented statistical arguments to remind the research community that a finding is less likely to be true if: 1) study size is small, 2) effect size is small, 3) a protocol is not pre-determined […]

Attending the recent BioNow Oncology event at Alderley Park, I was struck by the strength of an Oncology drug discovery interdisciplinary community in the North West, which hardly existed at all a few years ago. Or, perhaps more accurately, did exist but was hidden behind the tall walls of Pharma. Many ex-AstraZeneca scientists have emerged […]

Sign up for our newsletter

First Name

Last Name

Email

Complete this form and we'll send you our monthly newsletter, and occasional alerts when we have major announcements and collaboration opportunities. Every email we send will include a link to unsubscribe, and after 12 months we'll ask you if you want to stay opted-in. We won't share your data with any third-party. For more details, read our Privacy Policy

To comply with EU directives we now provide detailed information about the cookies we use. To find out more about cookies on this site, what they do and how to remove them, see our information about cookies. Click OK to continue using this site.OkRead more